Paeds SAQs · endocrinology-diabetes-and-growth
Hyperthyroidism and Graves disease — formative SAQs
Formative SAQs on distinguishing thyrotoxicosis from hyperthyroidism, confirming Graves disease through a suppressed TSH, raised free T4 and a positive TSH-receptor antibody, delivering symptom control with a beta-blocker and hormone control with carbimazole or methimazole, holding propylthiouracil for thyroid storm and first-trimester pregnancy, and recognising transient neonatal thyrotoxicosis in the infant of a mother with Graves disease.
On this page
Study tools
Target exams
SAQ 1 (10 marks)
A thirteen-year-old girl presents over four months with palpitations, a tremor, a five-kilogram weight loss despite an increased appetite, heat intolerance, anxiety and declining school performance. Her mother has noticed that her eyes look prominent. Examination reveals a heart rate of 110 beats per minute, a bounding pulse with a blood pressure of 130/60 mmHg, a fine tremor, lid retraction and mild proptosis, and a diffuse, smooth goitre with an audible bruit. Her thyroid function shows a TSH of less than 0.05 mU/L, a free T4 of 38 pmol/L and a positive TSH-receptor antibody. [1] [3]
a) Give the diagnosis and explain how the clinical and biochemical picture arises from the underlying autoimmune mechanism. (3 marks) [1]
b) Outline the immediate and long-term pharmacological management, naming the first-line antithyroid drug, the role of the beta-blocker, the two dosing regimens, and the reason propylthiouracil is avoided. (3 marks) [1] [6] [9]
c) Describe the two drug dangers that must be explained to the family at every prescription, their presenting features, and the immediate response. (2 marks) [9]
d) Discuss the prognosis after a two-to-three-year course of antithyroid drugs, the relapse rate, and the factors that predict relapse. (2 marks) [5] [6]
References6ShowHide
- [1]Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid, 2016.PMID 27521067
- [3]Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol, 2023.PMID 36848916
- [5]Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Léger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab, 2008.PMID 18628515
- [6]Léger J, Carel JC. MANAGEMENT OF ENDOCRINE DISEASE: Arguments for the prolonged use of antithyroid drugs in children with Graves' disease. Eur J Endocrinol, 2017.PMID 28381452
- [9]Rivkees SA, Mattison DR. Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use. Int J Pediatr Endocrinol, 2009.PMID 19946400
- [11]Polak M. Hyperthyroidism in early infancy: pathogenesis, clinical features and diagnosis with a focus on neonatal hyperthyroidism. Thyroid, 1998.PMID 9920374